Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma
Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies
ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL
2 Commerce Drive
Cranbury, NJ 08512